Ectodermal Dysplasia: Clinical Trials

4 trials for Ectodermal Dysplasia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 recruiting. 4 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 34Completed 3, Recruiting 1
Phase 21Completed 1

Follow Ectodermal Dysplasia: new trials by email Literature Review of Ectodermal Dysplasia trials Research Report on Ectodermal Dysplasia

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita
PTX-022 - Pachyonychia Congenita
Phase 3RecruitingPalvella Therapeutics, Inc.452022-11-152022-12-09
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
QTORIN 3.9% rapamycin anhydrous gel, Vehicle - Pachyonychia Congenita
Phase 3CompletedPalvella Therapeutics, Inc.872021-11-292024-08-29
VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita
PTX-022 - Pachyonychia Congenita
Phase 3CompletedPalvella Therapeutics, Inc.362020-09-012024-08-29
Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita
PTX-022, Placebo - Pachyonychia Congenita
Phase 2 / Phase 3CompletedPalvella Therapeutics, Inc.732019-04-012024-08-29

Narrower conditions

Pachyonychia Congenita (4)

Broader conditions

Abnormalities, Multiple (4)  ·  Congenital Abnormalities (4)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4)  ·  Genetic Diseases, Inborn (4)  ·  Nail Diseases (4)  ·  Skin Abnormalities (4)  ·  Skin Diseases (4)  ·  Skin Diseases, Genetic (4)  ·  Skin and Connective Tissue Diseases (4)

Sponsors

Palvella Therapeutics, Inc. (4)

Countries

United States (4)  ·  United Kingdom (1)

Top investigators

David Hansen, MD (2)  ·  Joyce Teng, MD (2)  ·  Amy Paller, MD (1)